Total trials
127
Active
4
Phase 3
45
Total enrollment
14,498
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| JNJ-77242113 | — | — | — | — | 2 | ||
| AAV5-hRKp.RPGR | — | — | — | — | — | 1 | |
| GnRH Agonist | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | 2 | ||
| Erdafitinib Intravesical Delivery System | — | — | — | — | — | 1 |
Next readouts
- 2021-06-09
- 2025-01-14
- 2025-03-11
- 2027-06-30
Top conditions
- Healthy26
- Multiple Myeloma10
- Schizophrenia9
- Pain7
- Hepatitis C, Chronic6
- Chronic Pain4
- Alzheimer's Disease4
- Cancer3
Frequently asked questions about Janssen Pharmaceutical K.K.
- How many clinical trials does Janssen Pharmaceutical K.K. have on ClinicalTrials.gov?
- Janssen Pharmaceutical K.K. is listed as the lead sponsor on 127 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Janssen Pharmaceutical K.K.'s trials are in Phase 3?
- 45 of Janssen Pharmaceutical K.K.'s trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Janssen Pharmaceutical K.K. focus on?
- Janssen Pharmaceutical K.K.'s most-studied conditions on ClinicalTrials.gov are Healthy, Multiple Myeloma, Schizophrenia, Pain, Hepatitis C, Chronic.
- When are Janssen Pharmaceutical K.K.'s next clinical trial readouts?
- Janssen Pharmaceutical K.K. has 4 upcoming primary-completion readouts tracked here; the soonest is “A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma”, expected around 2021-06-09.